1176 related articles for article (PubMed ID: 25713985)
1. Progress in biosimilar monoclonal antibody development: the infliximab biosimilar CT-P13 in the treatment of rheumatic diseases.
Braun J; Kudrin A
Immunotherapy; 2015; 7(2):73-87. PubMed ID: 25713985
[TBL] [Abstract][Full Text] [Related]
2. Scientific rationale behind the development and approval of biosimilar infliximab (CT-P13) in Europe.
Müller-Ladner U; Hong S; Oh C; Taylor P
Expert Rev Clin Immunol; 2015; 11 Suppl 1():S5-14. PubMed ID: 26395832
[TBL] [Abstract][Full Text] [Related]
3. Analysis of clinical trials of biosimilar infliximab (CT-P13) and comparison against historical clinical studies with the infliximab reference medicinal product.
Yoo DH; Oh C; Hong S; Park W
Expert Rev Clin Immunol; 2015; 11 Suppl 1():S15-24. PubMed ID: 26395833
[TBL] [Abstract][Full Text] [Related]
4. Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study.
Park W; Yoo DH; Jaworski J; Brzezicki J; Gnylorybov A; Kadinov V; Sariego IG; Abud-Mendoza C; Escalante WJ; Kang SW; Andersone D; Blanco F; Hong SS; Lee SH; Braun J
Arthritis Res Ther; 2016 Jan; 18():25. PubMed ID: 26795209
[TBL] [Abstract][Full Text] [Related]
5. A scientific update on biosimilar infliximab (CT-P13) in rheumatic diseases.
Taylor P
Expert Rev Clin Immunol; 2015; 11 Suppl 1():S1-4. PubMed ID: 26395831
[TBL] [Abstract][Full Text] [Related]
6. A review of CT-P13: an infliximab biosimilar.
McKeage K
BioDrugs; 2014 Jun; 28(3):313-21. PubMed ID: 24723086
[TBL] [Abstract][Full Text] [Related]
7. CT-P13 in the treatment of rheumatoid arthritis.
Yoo DH
Expert Rev Clin Immunol; 2017 Jul; 13(7):653-666. PubMed ID: 28571501
[TBL] [Abstract][Full Text] [Related]
8. CT-P13: design, development, and place in therapy.
Gabbani T; Deiana S; Annese V
Drug Des Devel Ther; 2017; 11():1653-1661. PubMed ID: 28652703
[TBL] [Abstract][Full Text] [Related]
9. Infliximab Biosimilar (CT-P13; Infliximab-dyyb): A Review in Autoimmune Inflammatory Diseases.
Blair HA; Deeks ED
BioDrugs; 2016 Oct; 30(5):469-480. PubMed ID: 27650650
[TBL] [Abstract][Full Text] [Related]
10. Biosimilar Monoclonal Antibodies for Inflammatory Bowel Disease: Current Comfort and Future Prospects.
Gecse KB; Lakatos PL
Drugs; 2016 Oct; 76(15):1413-1420. PubMed ID: 27638739
[TBL] [Abstract][Full Text] [Related]
11. The rise of biosimilars: potential benefits and drawbacks in rheumatoid arthritis.
Yoo DH
Expert Rev Clin Immunol; 2014 Aug; 10(8):981-3. PubMed ID: 24961712
[TBL] [Abstract][Full Text] [Related]
12. A 5-year Retrospective Analysis of Drug Survival, Safety, and Effectiveness of the Infliximab Biosimilar CT-P13 in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis.
Kim TH; Lee SS; Park W; Song YW; Suh CH; Kim S; Lee YN; Yoo DH
Clin Drug Investig; 2020 Jun; 40(6):541-553. PubMed ID: 32328979
[TBL] [Abstract][Full Text] [Related]
13. Comparative effectiveness of the biosimilar CT-P13.
Yoo DH
J Comp Eff Res; 2017 Nov; 6(8):693-712. PubMed ID: 29172717
[TBL] [Abstract][Full Text] [Related]
14. A review of the literature analyzing benefits and concerns of infliximab biosimilar CT-P13 for the treatment of rheumatologic diseases: focus on interchangeability.
Becciolini A; Raimondo MG; Crotti C; Agape E; Biggioggero M; Favalli EG
Drug Des Devel Ther; 2017; 11():1969-1978. PubMed ID: 28721016
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study.
Park W; Yoo DH; Miranda P; Brzosko M; Wiland P; Gutierrez-Ureña S; Mikazane H; Lee YA; Smiyan S; Lim MJ; Kadinov V; Abud-Mendoza C; Kim H; Lee SJ; Bae Y; Kim S; Braun J
Ann Rheum Dis; 2017 Feb; 76(2):346-354. PubMed ID: 27117698
[TBL] [Abstract][Full Text] [Related]
16. The immunogenicity of biosimilar infliximab: can we extrapolate the data across indications?
Ben-Horin S; Heap GA; Ahmad T; Kim H; Kwon T; Chowers Y
Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():27-34. PubMed ID: 26395532
[TBL] [Abstract][Full Text] [Related]
17. Biosimilar infliximab: an expert view.
Genazzani A; Altomare G; Balato N; Cusano F; De Pità O; Loconsole F; Micali G; Piaserico S; Girolomoni G
G Ital Dermatol Venereol; 2015 Aug; 150(4):449-59. PubMed ID: 25747260
[TBL] [Abstract][Full Text] [Related]
18. Pharmacology of biosimilar candidate drugs in rheumatology: a literature review.
Araújo F; Cordeiro I; Teixeira F; Gonçalves J; Fonseca JE
Acta Reumatol Port; 2014; 39(1):19-26. PubMed ID: 24811458
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the Cross-reactivity of Antidrug Antibodies to CT-P13 and Infliximab Reference Product (Remicade): An Analysis Using Immunoassays Tagged with Both Agents.
Reinisch W; Jahnsen J; Schreiber S; Danese S; Panés J; Balsa A; Park W; Kim J; Lee JU; Yoo DH
BioDrugs; 2017 Jun; 31(3):223-237. PubMed ID: 28497221
[TBL] [Abstract][Full Text] [Related]
20. Biosimilar monoclonal antibodies: preclinical and clinical development aspects.
Gonçalves J; Araújo F; Cutolo M; Fonseca JE
Clin Exp Rheumatol; 2016; 34(4):698-705. PubMed ID: 27383278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
